Diabetes mellitus and raised serum triglyceride concentration in treated hypertension—are they of prognostic importance? Observational study

BMJ

Volumn 313, Issue 7058, 1996, Pages 660-663

  Samuelsson, Ola ^a   Andersson, Ove ^a   Persson, Bengt ^a   Hedner, Thomas ^a   Pennert, Kjell ^b   Berglund, Goran ^c   Wedel, Hans ^d   Wilhelmsen, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Clinical Data Care AB   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORBIDITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-AGONISTS; BENZOTHIADIAZINES; CHOLESTEROL; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIURETICS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; TRIGLYCERIDES;

EID: 0029777293     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.313.7058.660     Document Type: Article

References (60)

1. The 1993 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. Blood Pressure 1993; 2: 86 100.
2. The 1992 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1993; 153: 154–183.
3. Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.
4. SBU—the Swedish Council on Technology Assessment in Health Care. Moderately elevated blood pressure. J Intern Med 1995; 238(suppl 737):1–128.
5. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203–209.
6. Weinberger MH. Antihypertensive therapy and lipids. Paradoxical influences on cardiovascular disease risk. Am J Med 1986; 80(suppl 2A):64–70.
7. Pollare T Disturbances in carbohydrate and lipid metabolism in patients with primary hypertension with special references to the effects of pharmacological antihypertensive treatment [thesis]. Uppsala, Sweden: Uppsala University, 1989.
8. Reaven GM. Treatment of hypertension: focus on prevention of coronary heart disease. J Clin Endocrinol Metab 1993; 76: 537–540.
9. Sowers JR. Is hypertension an insulin resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. Am Heart J 1991; 122: 932–935.
10. Risks of antihypertensive therapy. Lancet [editorial]. 1986; 2: 1075–1076.
11. Elliot JW. Glucose and cholesterol elevations during thiazide therapy: intention-to-treat versus actual on-therapy experience. Am J Med 1995; 99: 261–269.
12. Wilhelmsen L, Tibblin G, Werko L. A primary preventive study in Gothenburg, Sweden. Prev Med 1972; 1: 153–160.
13. Samuelsson O. Hypertension in middle-aged men: management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand 1985; 702(suppl):1–79.
14. World Health Organisation Expert Committee on Diabetes Mellitus Second report. Geneva: WHO, 1980. (Technical report series, No 646.)
15. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (Series B) 1972; 34: 187 220.
16. Altman DG, De Stavola BL. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 1994; 13: 301–341.
17. SAS/STAT software The PHREG procedure. SAS Institute, Cary, NC, 1991. (Technical report.)
18. Weber MA, Laragh J. Hypertension: steps forward and steps backward. The Joint National Committee fifth report. Arch Intern Med 1993; 153: 149–152.
19. Nilsson P, Andersson DKG, Andersson P-E, Schwan A, Ostlind B, Malmborg R, et al. Cardiovascular risk factors in treated hypertensives—a nation-wide, cross-sectional study in Sweden. J Intern Med 1993; 233: 239–245.
20. Northcote RJ. Metabolic parameters: how important are pharmacologically-induced changes? J Hypertens 1991; 9(suppl 7):21–5.
21. Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994; 309: 226–230.
22. Freis ED. The efficacy and safety of diuretics in treating hypertension. Ann Intern Med 1995; 122: 223–226.
23. Report by the Trial Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980; 1: 1261–1267.
24. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the multiple risk factor intervention trial. Prev Med 1986; 15: 254–273.
25. Systolic Hypertension in the Elderly Program Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265: 3255–3264.
26. Rose G. Incubation period of coronary heart disease. BMJ 1982; 284: 1600–1601.
27. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the multiple risk factor intervention trial. JAMA 1990; 263: 1795 1801.
28. Hypertension, Detection and Follow-up Program Cooperative Group. Persistance of reduction in blood pressure and mortality of participants in the hypertension, detection and follow-up program. JAMA 1988; 259: 2113–2122.
29. Wolfe RA, Strawderman RL. Logical and statistical fallacies in the use of Cox regression models. Am J Kidney Dis 1996; 27: 124–129.
30. Kannel WB. Risk factors in hypertension. J Clin Cardiovasc Pharmacol 1989; 13(suppl 1):S4–10.
31. Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. Br Heart J 1988; 59: 364–378.
32. The International Prospective Primary Prevention Study in Hypertension Collaborative Group. Cardiovascular risk and risk factors in a randomised trial of treatment based on (beta) blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 1985; 3: 379–392.
33. Collins P, Fox K. The pathogenesis of atheroma and the rationale for its treatment. Eur Heart J 1992; 13: 560–565.
34. Schwartz CJ, Kelley JL, Valente AJ, Cayatte AJ, Sprague EA, Rozed MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992; 15: 1156–1167.
35. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992; 20: 736–744.
36. Reaven GM. Relationship between insulin resistance and hypertension. Diabetes care 1991; 14: 33–38.
37. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–194.
38. Yudkin JS. Hypertension and non-insulin diabetes mellitus. Chicken, egg, tablets, or insulin resistance? BMJ 1991; 303: 730–731.
39. Julius S, Gubrandsson T, Jamerson K, Andersson O. The interconnection between sympathetics, microcirculation and insulin resistance in hypertension. Blood Pressure 1992; 1: 9 19.
40. Haffner SM. Insulin and blood pressure: fact or fantasy? J Clin Endocrinol Metab 1993; 76: 541–543.
41. Jarret RJ. In defence of insulin: a critique of syndrome X. Lancet 1992; 2: 469–471.
42. Standley PR, Mohamad HB, Suxer JR. Vascular insulin abnormalities, hypertension and accelerated atherosclerosis. Am J Kidney Dis 1993; 21(suppl 3):39–46.
43. Frayn KN, Coppack SW. Insulin resistance, adipose tissue and coronary heart disease. Clin Sci 1992; 82: 1 8.
44. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor? Diabetes Care 1995; 18: 1299–1304.
45. Morales PA, Braxton DM, Rodolfo AV, Hauda H, Stern MP, Haffner SM. Incidence of NIDDM and impaired glucose tolerance in hypertensive subjects. The San Antonio heart study. Diabetes 1993; 42: 154–161.
46. Bengtsson C, Blohme G, Lapidus L, Lindquist O, Lundgren H, Nystrom E, et al. Do antihypertensive drugs precipitate diabetes? BMJ 1984; 289: 1495–1497.
47. Skarfors ET, Lithell HO, Selinus I, Aberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 1989; 298: 1147–1152.
48. Skarfors ET, Selinus I, Lithell HO. Risk factors for development of non-insulin dependent diabetes mellitus in middle aged men. Results from a 10 year follow-up of participants in an Uppsala health survey. BMJ 1991; 303: 755–760.
49. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of “syndrome X.” Am J Hypertens 1993; 6(suppl 4):123–6.
50. Kannel W, McGee D. Diabetic and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–2038.
51. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: The Whitehall study. Lancet 1980; 1: 1373–1376.
52. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989; 299: 1127–1131.
53. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434–444.
54. Austin MA. Plasma triglyceride and coronary heart disease. Atherosclerosis and Thrombosis 1991; 11: 2 14.
55. Moser M. Current hypertension management: separating fact from fiction. Cleve Clin J Med 1993; 60: 27 37.
56. Rosman J, Weidmann P, Ferrari P. Antihypertensive drugs and serum lipoproteins. J Drug Dev 1990; 3(suppl 1):129–39.
57. The Captopril Prevention Project Group. The captopril prevention project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertens 1990; 8: 985–990.
58. Dahlof B, Hansson L, Lindholm L, Schersten B, Wester PO, Ekbom T, et al. STOP-hypertension 2: a prospective intervention trial of “newer” versus “older” treatment alternatives in essential hypertension. Blood Pressure 1993; 2: 137–142.
59. The NORDIL Group. The Nordic diltiazem study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure 1993; 2: 312–321.
60. Sever P, Beevers G, Bulpit C, Lever A, Ramsay L, Reid J, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983–987.